Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication a population-based study

JAMA Psychiatry

Volumn 71, Issue 3, 2014, Pages 319-325

  Chang, Zheng ^a   Lichtenstein, Paul ^a   D'Onofrio, Brian M ^b   Sjölander, Arvid ^a   Larsson, Henrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ACCIDENT; ACCIDENT PRONENESS; ADULT; ADULT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; ATTRIBUTABLE RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT SAFETY; REGISTER; RISK ASSESSMENT; RISK REDUCTION; SERIOUS TRANSPORT ACCIDENT; YOUNG ADULT;

ACCIDENTS, TRAFFIC; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; SEX FACTORS; SWEDEN; YOUNG ADULT;

EID: 84896775749     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.4174     Document Type: Article

References (34)

1. World Health Organization (WHO). Global status report on road safety: time for action: 2009.http://whqlibdoc.who.int/publications/2009 /9789241563840-eng.pdf. Accessed April 11, 2013.
2. Lam LT. Distractions and the risk of car crash injury: the effect of drivers' age. J Safety Res. 2002;33(3):411-419.
3. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-128.
4. Cox DJ, Cox BS, Cox J. Self-reported incidences of moving vehicle collisions and citations among drivers with ADHD: a cross-sectional survey across the lifespan. Am J Psychiatry. 2011;168(3):329-330.
5. Cox DJ, Madaan V, Cox BS. Adult attention-deficit/hyperactivity disorder and driving: why and how to manage it. Curr Psychiatry Rep. 2011;13(5):345-350.
6. Jerome L, Habinski L, Segal A. Attention-deficit/ hyperactivity disorder (ADHD) and driving risk: a review of the literature and amethodological critique. Curr Psychiatry Rep. 2006;8(5):416-426.
7. Redelmeier DA, Chan WK, Lu H. Road trauma in teenage male youth with childhood disruptive behavior disorders: a population based analysis. PLoS Med. 2010;7(11):e1000369. doi:10.1371/journal.pmed.1000369.
8. Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin NorthAm. 2004;27(2):233-260.
9. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-495.
10. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(1):149-159.
11. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67. doi:10.1186/1471-244X-10-67.
12. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
13. Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012;46(4):484-491.
14. Fredriksen M, Halmoy A, Faraone SV, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-527.
15. Singh I. Beyond polemics: science and ethics of ADHD. Nat Rev Neurosci. 2008;9(12):957-964.
16. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-667.
17. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months [published correction appears in Pharmacoepidemiol Drug Saf. 2008;17(5):533]. Pharmacoepidemiol Drug Saf. 2007;16(7):726-735.
18. Zetterqvist J, Asherson P, Halldner L, Langstrom N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128(1):70-77.
19. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194(3):273-277.
20. Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006-2014.
21. Allison PD. Fixed Effects Regression Models. Thousand Oaks, CA: Sage; 2009.
22. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum. 1953;9(3):531-541.
23. Chen YQ, Hu C,Wang Y. Attributable risk function in the proportional hazards model for censored time-to-event. Biostatistics. 2006;7(4):515-529.
24. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007;20(4): 386-392.
25. Massie DL, Campbell KL, Williams AF. Traffic accident involvement rates by driver age and gender. Accid Anal Prev. 1995;27(1):73-87.
26. Toroyan T, Peden M. Youth and Road Safety. Geneva, Switzerland:World Health Organization; 2007.
27. Castle L, Aubert RE, Verbrugge RR, Khalid M,Epstein RS. Trends in medication treatment for ADHD. J AttenDisord. 2007;10(4):335-342.
28. Zoëga H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand. 2011;123(5):360-367.
29. Asherson P, Akehurst R, Kooij JJ, et al. Under diagnosis of adult ADHD: cultural influences and societal burden. J AttenDisord. 2012;16(5)(suppl): 20S-38S.
30. Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8(5):655-672.
31. Cox DJ, Davis M, Mikami AY, Singh H, Merkel RL, Burket R. Long-actingmethylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2012;32(2):225-230.
32. Larsson H, Rydén E, Boman M, Långström N, Lichtenstein P, Landén M. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2013;203(2):103-106.
33. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31:419-437.
34. Redelmeier DA, Yarnell CJ, ThiruchelvamD, Tibshirani RJ. Physicians' warnings for unfit drivers and the risk of trauma from road crashes. N Engl J Med. 2012;367(13):1228-1236.